Bibliography for the Drug Target Identification from Microbial Genomes

Bibliography

_________________________________________________________________________

Identification and Validation of Drug Targets

153

BIBLIOGRAPHY

. .

Adams, G. (2000). Lecture Notes, Microbiology, 29 Feb. 2000.

Akerley, B. J., Rubin, E. J., Camilli, A., Lampe, D. J., Robertson, H. M. and

Mekalanos, J. J. (1998). Systematic identification of essential genes by in

vitro mariner mutagenesis. Proc. Natl. Acad. Sci. USA., 95, 8927-8932.

Altschul S. F. (1990). Basic local alignment search tool. J. Mol. Biol., 215, 403-

410.

Anderson, A. A. (2003). Chemistry and Biology, 10, 787.

Aradi, I. and Erdi, P. (2006). Computational neuropharmacology, dynamical

approaches in drug discovery. Trends Pharmacol. Sci., 27, 240-243.

Arigoni, F., Talabot, F., Peitsch, M., Edgerton, M. D., Meldrum, E., Allet, E., Fish,

R., Jamotte, T., Curchod, M. L. and Loferer, H. (1998). A genome-based

approach for the identification of essential bacterial genes. Nat. Biotechnol.,

16, 851-856.

Aronov, A. M., Balakin, K. V., Kiselyov, A., Varma-O’Brien, S. and Ekins, S.

(2006). Applications of QSAR methods to ion channels. In, Ekins S (ed).

Computational Toxicology, Risk Assessment for Pharmaceutical and

Environmental Chemicals. John Wiley and Sons, Hoboken, NJ.

Bibliography

_________________________________________________________________________


154

Auckland, C., Teare, L., Cooke, F., Kaufmann, M. E., Warner, M., Jones, G.,

Bamford, K., Ayles, H., Johnson, A. P. (2002). J. Antimicrob. Chemother. ,

50, 743−746.

Badarinarayana, V., Estep, P. W., Shendure, J., Edwards, J., Tavazoie, S., Lam,

F. and Church, G. M. (2001). Selection analyses of insertional mutants

using subgenic-resolution arrays. Nat. Biotechnol., 19, 1060-1065.

Bairoch, A., Apweiler, R., Wu, C. H., Barker, W. C., Boeckmann, B., Ferro, S.,

Gasteiger, E., Huang, H., Lopez, R. and Magrane, M. (2005). The Universal

Protein Resource (UniProt). Nucleic Acids Res., 33, D154–D159.

Bajorath, J. (2002). Nat. Rev. Drug Discov., 1, 882-894.

Barbachyn, M. R., Brickner, S. J., Gadwood, R. C., Garmon, S. A., Grega, K. C.,

Hutchinson, D. K., Munesada, K., Reischer, R. J., Taniguchi, M.,

Thomasco, L. M., Toops, D. S., Yamada, H., Ford, C. W., and Zurenko, G.

E. (1998). Adv. Exp. Med. Biol., 456, 219−238.

Bartel, P. (1993). Elimination of false positives that arise in using the two-hybrid

system. Biotechniques, 14, 920-924.

Becker, O. M., Shacham, S., Marantz, Y. and Noiman, S. (2003). Curr. Opin. Drug

Discov. Devel. , 6, 353-361.

Becker, O. M., Shacham, S., Topf, M. and Naor, Z. (2000). World Patent, WO-

02_15106-A2.

Bibliography

_________________________________________________________________________


155

Beddell, C. R. (1976). Br. J. Pharmacol., 57, 201. [PMID, 938794].

Behr, M. A. (1999). Comparative genomics of BCG vaccines by whole-genome

DNA microarray. Science, 284, 1520-1523.

Benton, B. L., J. Ving, F. Malouin, P. K. Martin, M. B. Schmid, and D. Sun. March

(2000). Methods of screening for compounds active on Staphylococcus

aureus target genes. US Patent, 6, 37-123.

Benton, B. L., J. Ving, F. Malouin, P. K. Martin, M. B. Schmid, and D. Sun. (2001).

Methods of screening for compounds active on Staphylococcus aureus

target genes. US Patent, 6, 228, 588.

Berg, C. M. and Berg, D. A. (1996). Transposable element tools for microbial

genetics. In: Escherichia coli and Salmonella (Neidhardt F. C. ed. ), pp.

2588-2612.

Bernal, A., Ear, U. and Kyrpides N. (2001). Genomes OnLine Database (GOLD), a

monitor of genome projects world-wide. Nucleic Acids Res. , 29, 126-127.

Bernstein, F. C., Koetzle, T. F., Williams, T. F., Meyer, G. J. B., Jr, Brice, M. D.,

Rodgers, J. R., Kennard, O., Shimanouchi, T. and Tasumi, M. (1977). The

Protein Data Bank, A computer-based archival file for macromolecular

structures. J. Mol. Biol., 112, 535–542.

Bibliography

_________________________________________________________________________


156

Bissantz, C., Bernard, P., Hibert, M. and Rognan, D. (2003). Protein-based virtual

screening of chemical databases. II. Are homology models of G-protein

coupled receptors suitable targets? Proteins, 50, 5-25.

Blattner, F. R. (1997). The complete genome sequence of Escherichia coli K-12.

Science, 277, 1453-1462.

Block, P., Sotriffer, C. A., Dramburg, I. and Klebe, G. (2006). AffinDB, Afreely

accessible database of affinities for protein–ligand complexes from the

PDB. Nucleic Acids Res., 34, D522–D526.

Blundell, T. L. (1972). Adv. Protein Chem., 26, 279.

Blundell, T. L. (1996). Nature, 384, 23. [PMID, 8895597].

Bonacci, T. M., Mathews, J. L., Yuan, C., Lehmann, D. M., Malik, S. and Wu, D.

(2006). Differential targeting of Gbetagamma-subunit signaling with small

molecules. Science, 312, 443-446.

Brewerton, S. C., Dore, A. S., Drake, A. C., Leuther, K. K. and Blundell, T. L.

(2004). Structural analysis of DNA-PKcs, modelling of the repeat units

and insights into the detailed molecular architecture. J. Struct. Biol., 145,

295-306.

C. R. Beddell (1976), Br. J. Pharmacol., 57, 201 (1976). [PMID, 938794].

Cacace, A. (2003). Drug Discovery Today, 8, 785. [PMID, 12946641]

Campbell, S. F. (2000). Clin. Sci., 99, 255. [PMID, 10995589].

Bibliography

_________________________________________________________________________


157

Carper, S. W., Duffy, J. J. and Gerner, E. W. (1987). Cancer Res., 47, 5249-5255.

Cassell, G. H. and Mekalanos, J. (2001). JAMA, 285, 601−605.

Chalker, A. F., Minehart, H. W., Hughes, N. J., Koretke, K. K., Lonetto, M. A.,

Brinkman, K. K., Warren, P. V., Lupas, A., Stanhope, M. J., Brown, J. R.

and Hoffman, P. S. (2001). Systematic identification of selective essential

genes in Helicobacter pylori by genome prioritization and allelic

replacement mutagenesis. J. Bacteriol. , 183, 1259-1268.

Chang, C. and Swaan, P. W. (2005). Computational approaches to modeling drug

transporters. Eur. J. Pharm. Sci., 27, 411-424.

Chang, C., Bahadduri, P. M., Polli, J. E., Swaan, P. W. and Ekins, S. (2006a).

Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab.

Dispos., 34, 1976-1984.

Chang, C., Ekins, S., Bahadduri, P. and Swaan, P. W. (2006b).

Pharmacophorebased discovery of ligands for drug transporters. Adv. Drug

Del. Rev., 58, 1431-1450.

Chen, Y. Z. and Ung, C. Y. (2001). Prediction of potential toxicity and side effect

protein targets of a small molecule by a ligand-protein inverse docking

approach. J. Mol. Graph. Model., 20, 199-218.

Bibliography

_________________________________________________________________________


158

Chen, Y. Z. and Zhi, D. G. (2001). Ligand-protein inverse docking and its potential

use in the computer search of protein targets of a small molecule. Proteins,

43, 217-226.

Choi, V. (2005). YUCCA, an efficient algorithm for small-molecule docking. Chem.

Biodivers., 2, 1517-1524.

Christman, M. F., Morgan, R. W., Jacobson, F. S. and Ames, B. N. (1985). Cell,

41, 753-762

Clements, J. M., Beckett, R. P., Brown, A., Catlin, G., Lobell, M., Palan, S.,

Thomas, W., Whittaker, M., Wood, S., Salama, S., Baker, P. J., Rodgers, H.

F., Barynin, V., Rice, D. W., and Hunter, M. G. (2001). Antimicrob. Agents

Chemother., 45, 563−570.

Colas, P. (1996). Genetic selection of peptide aptamers that recognize and inhibit

cyclin-dependent kinase 2. Nature, 380, 548-550.

Connors, T. A. (1984). Antitumour Drug Resistance (Fox, B. W. and Fox, M., eds.),

pp. 403-422, Springer-Verlag, Berlin, Heidelberg, New York, Tokyo.

Cummings, M. D., DesJarlais, R. L., Gibbs, A. C., Mohan, V. and Jaeger, E. P.

(2005). Comparison of automated docking programs as virtual screening

tools. J. Med. Chem., 48(4), 962-976. [PubMed, 15715466].

Cundliffe, E. (1984). Br. Med. Bull., 40, 61-67.

Bibliography

_________________________________________________________________________


159

Dajani, R., Cleasby, A., Neu, M., Wonacott, A. J., Jhoti, H. and Hood, A. M.

(1999). X-ray crystal structure of human dopamine sulfotransferase,

SULT1A3. J. Biol. Chem., 53, 37862-37868.

Danchin, A., Medigue, C., Gascuel, O., Soldano, H. and Henaut, A. (1991). From

data banks to data bases. Res. Microbiol., 142, 913-916.

Davie, E. W. (1991). Biochemistry, 30, 10363. [PMID, 1931959].

Davie, E. W. (1991). Biochemistry, 30, 10363. [PMID, 1931959].

Davis, A. M. (2003). Angew. Chem. Int. Ed., 42, 2718. [PMID, 12820253].

De Graaf, C., Vermeulen, N. P. and Feenstra, K. A. (2005). Cytochrome P450 in

silico, an integrative modeling approach. J. Med. Chem., 48, 2725-2755.

De Groot, M. J. and Ekins, S. (2002). Pharmacophore modeling of cytochromes

P450. Adv. Drug. Del. Rev., 54, 367-383.

De, Groot, M. J. (2006). Designing better drugs, predicting cytochrome P450

metabolism. Drug Discov. Today, 11, 601-606.

Deisenhofer, J. and Smith, J. L. (2001). Curr. Opin. Struc. Bio., 11, 701.

Demple, B., Sedgwick, B., Robins, P., Totty, N., Waterfield, M. D. and Lindahl, T.

(1985). Proc. Natl. Acad. Sci. U. S. A., 82, 2688-2692.

Di Masi, J. A. (2002). The value of improving the productivity of the drug

development process. Pharmacoeconomics, 20 (Suppl. 3), 1-10.

Bibliography

_________________________________________________________________________


160

Di Santo, R., Fermeglia, M., Ferrone, M., Paneni, M. S., Costi, R. and Artico, M.

(2005). Simple but highly effective three-dimensional chemical-feature-

based pharmacophore model for diketo acid derivatives as hepatitis C virus

RNA-dependent RNA polymerase inhibitors. J. Med. Chem., 48, 6304-6314.

Dooley, A. J., Shindo, N., Taggart, B., Park, J. G. and Pang, Y. P. (2006). From

genome to drug lead, identification of a small-molecule inhibitor of the

SARS virus. Bioorg. Med. Chem. Lett., 16, 830-833.

Drews, J. (2000). Drug discovery, a historical perspective. Science. 17, 287(5460),

1960-1964.

Drews, J. (2000). Science, 287, 1960. [PMID, 10720314].

Ecker, D. J. and Griffey, R. H. (1999). Drug Discovery Today, 4, 420. [PMID,

10461152].

Edwards, S., Zhu, J. and Caurie, C. (2005). Integrating QTL and high-density SNP

analyses in mice to identify Insig2 as a susceptibility gene for plasma

cholesterol levels. Genomics, 86, 505-517.

Ekins, S., Bravi, G., Binkley, S., Gillespie, J. S., Ring, B. J. and Wikel, J. H.

(1999). Three and four dimensional-quantitative structure activity

relationship analyses of CYP3A4 inhibitors. J. Pharmacol. Exp. Ther., 290,

429-438.

Bibliography

_________________________________________________________________________


161

Ekroos, M. and Sjogren, T. (2006). Structural basis for ligand promiscuity in

cytochrome P450 3A4. Proc. Natl. Acad. Sci. USA, 103, 13682-13687.

Enyedy, I. (2001). J. Med. Chem., 44, 1349. [PMID, 11311057].

Enyedy, I. (2001). J. Med. Chem., 44, 4313. [PMID, 11728179].

Evers, A. and Klebe, G. (2004). Successful virtual screening for a submicromolar

antagonist of the neurokinin-1 receptor based on a ligand-supported

homology model. J. Med. Chem., 47, 5381-5392.

Evers, A., Gohlke, H. and Klebe, G. (2003). Ligand-supported homology modelling

of protein binding-sites using knowledge-based potentials. J. Mol. Biol., 334,

327-345.

Evers, A. and Klabunde, T. (2005). Structure-based drug discovery using GPCR

homology modeling, successful virtual screening for antagonists of the

alpha1A adrenergic receptor. J. Med. Chem., 48,1088-1097.

Ewing, T. J., Makino, S., Skillman, A. G. and Kuntz, I. D. (2001). DOCK 4. 0,

search strategies for automated molecular docking of flexible molecule

databases. J. Comput. Aided Mol. Des., 15, 411-428.

Flohr, S., Kurz, M., Kostenis, E., Brkovich, A., Fournier, A. and Klabunde, T.

(2002). J. Med. Chem., 45, 1799-1805.

Frantz, S. and Smith, A. (2003). New drug approvals for 2002. Nat. Rev. Drug.

Discov., 2, 95-96.

Bibliography

_________________________________________________________________________


162

Freiberg, C. (2001). Novel computational methods in anti-microbial target

identification. Drug Discov. Today, 6, S72-S80.

Freiberg, C., Wieland, B., Spaltmann, F., Ehlert, K., Brotz, H. and Labischinski, H.

(2001). Identification of novel essential Escherichia coli genes conserved

among pathogenic bacteria. J. Mol. Microbiol. Biotechnol., 3, 483-489.

Frosch, M. and Reidl, J. (1998). Genomics in infectious diseases, approaching the

pathogens. Trends in Microbiology., 6 (9), 346-349.

Gallo, Robert, C. (1990). Journal of Acquired Immune Deficiency Syndromes.

Lippincott Williams and Wilkins, WK Health.

Galperin, M. Y. and Koonin, E. V. (1999). Searching for drug targets in microbial

genomes. Current Opinion in Biotechnology, 10, 571-578.

Gamage, N. U., Duggleby, R. G., Barnett, A. C., Tresillian, M., Latham, C. F. and

Liyou, N. E. (2003). Structure of a human carcinogenconverting enzyme,

SULT1A1. J. Biol. Chem., 278, 7655-7662.

Gerstein, M. (2000). Integrative database analysis in structural genomics. Nature,

Structural Biology Sup., 960-963.

Gerstein, M. and Jansen, R. (2000). The current excitement in bioinformatics -

analysis of whole-genome expression data, how does it relate to protein

structure and function? Current Opinion in Structural Biology, 10, 574-584.

Ghosh, S. (2001). Curr. Cancer Drug Targets, 1, 129. [PMID, 12188886].

Bibliography

_________________________________________________________________________


163

Glen, R. C. (1995). J. Med. Chem., 38, 3566. [PMID, 7658443].

Goodford, P. J. (1980). Br. J. Pharmacol., 68, 741. [PMID, 7378645].

Gopalakrishnan, B., Aparna, V., Jeevan, J., Ravi, M. and Desiraju, G. R. (2005).

A virtual screening approach for thymidine monophosphate kinase inhibitors

as antitubercular agents based on docking and pharmacophore models.

J. Chem. Inf. Model, 45, 1101-1108.

Grabowski, H., Vernon, J. and DiMasi, J. A. (2002). Returns on research and

development for 1990s new drug introductions. Pharmacoeconomics,

20 (Suppl. 3), 11-29.

Grant, S. F., Thorleifsson, G., Reynisdottir, I., Benediktsson, R. and Manolescu, A.

(2006). Variant of transcription factor 7-like 2 (TCF7L2). gene confers risk of

type 2 diabetes. Nat Genet, 38, 320-323.

Gray, N. S. (1998). Exploiting chemical libraries, structure and genomics in the

search for kinase inhibitors. Science, 281, 533-538.

Greer, J. (1994). J. Med. Chem., 37, 1035. [PMID, 8164249].

Grigoriev, I. V. and Kim, S-H. (1999). Detection of protein fold similarity based on

correlation of amino acid properties. Proc. Natl. Acad. Sci. USA., 96, 14318-

14323.

Grzybowski, B. A., Ishchenko, A. V., Kim, C-K., Topalov, G., Chapman, R. and

Christianson, D. W. (2002). Combinatorial computational method gives new

Bibliography

_________________________________________________________________________


164

picomolar ligands for a known enzyme. Proc. Natl. Acad. Sci. USA, 99,

1270-1273.

Haines, J. L., Hauser, M. A., Schnidt, S., Scott, W. K. and Olson, L. M. (2005).

Complement factor H variant increases the risk of age-related macular

degeneration. Science, 308, 419-421.

Hajduk, P. J., Huth, J. R. and Tse, C. (2005). Predicting protein druggability. Drug

Discov. Today, 10, 1675-1682.

Hamer, L., DeZwaan, T. M., Montenegro-Chamorro, M. V., Frank, S. A. and

Hamer, J. E. (2001). Recent advances in large-scale transposon

mutagenesis. Curr. Opin. Chem. Biol., 5, 67-73.

Hansch, C., Lien, E. J. and Helmer, F. (1968). Structure-activity correlations in the

metabolism of drugs. Arch. Biochem. Biophys., 128, 319-330.

Haq, I. (2002). Arch. Biochem Biophys., 403, 1. [PMID, 12061796].

Hardy, L. W. and Malikayil, A. (2003). Curr. Drug Discov., 15.

Hare, R. S., Walker, S. S., Dorman, T. E., Greene, J. R., Guzman, L. M., Kenney,

T. J., Sulavik, M. C., Baradaran, K., Houseweart, C., Yu, H. Y., Foldes

Motzer, Z., Walbridge, M., Shimer, G. H. and Shaw, K. J. (2001). Genetic

footprinting in bacteria. J. Bacteriol., 183, 1694-1706.

Heinemann, J. A. (1999). How antibiotics cause antibiotic resistance. Drug

Discovery Today, 4, 72-79.

Bibliography

_________________________________________________________________________


165

Herbert, A., Gerry, N. P., McQueen, M. B., Heid, I. M. and Pfeufer, A. (2006). A

common genetic variant is associated with adult and childhood obesity.

Science, 312, 279-283.

Hinton, J. C. D. (1997). The Escherichia coli genome sequence, The end of an era

or the start of the FUN? Mol. Microbiol., 26, 417-422

Holm, L. and Sander, C. (1993). Protein structure comparison by alignment of

distance matrices. Journal of Molecular Biology, 233, 123-138.

Honglin Li, Zhenting Gao, Ling Kang, Hailei Zhang, Kun Yang, Kunqian Yu,

Xiaomin Luo, Weiliang Zhu, Kaixian Chen, Jianhua Shen, Xicheng Wang,

and Hualiang Jiang (2006). TarFisDock, a web server for identifying drug

targets with docking approach. Nucleic Acids Research, Vol. 34, Web

Server issue W219-W224.

Hood, D. W. (1999). The utility of complete genome sequences in the study of

pathogenic bacteria. Parasitology, 118, S3-S9.

Hopkins, A. L. and Groom, C. R. (2002). The druggable genome. Nature Rev.

Drug Discov., 1, 727-730.

Horn, F., Weare, J., Beukers, M. W., Horsch, S. and Bairoch, A. (1998). GPCRDB,

An information system for G protein-coupled receptors. Nucleic Acids Res.,

26, 275-279.

Bibliography

_________________________________________________________________________


166

Huang, C. M., Elmets, C. A., Tang, D. C., Li, F. and Yusuf, N. (2004). Proteomics

reveals that proteins expressed during the early stage of Bacillus anthracis

infection are potential targets for the development of vaccines and drugs.

Genomics Proteomics Bioinformatics, 2, 143-151.

Huang, J. and Schreiber, S. L. (1997). A yeast genetic system for selecting small

molecule inhibitors of protein-protein interactions in nanodroplets. Proc.

Natl. Acad. Sci. USA, 94, 13396-13401.

Hutchison, C. A., Peterson, S. N., Gill, S. R., Cline, R. T., White, O., Fraser, C. M.,

Smith, H. O. and Venter, J. C. (1999). Global transposon mutagenesis and

a minimal mycoplasma genome. Science, 286, 2165-2169.

Huynen, M. A. (1997). Trends Genet., 13, 389. [PMID, 9351339].

Itaya, M. (1995). An estimation of minimal genome size required for life. FEBS

Lett., 362, 257-260.

Jenkins, J. L., Kao, R. Y. and Shapiro, R. (2003). Proteins, 50, 81-93.

Jenks, P. J., Chevalier, C., Ecobichon, C. and Labigne, A. (2001). Identification of

nonessential Helicobacter pylori genes using random mutagenesis and loop

amplification. Res. Microbiol., 152, 725-734.

Ji, Z. L., Wang, Y., Yu, L., Han, L. Y., Zheng, C. J. and Chen, Y. Z. (2006). In silico

search of putative adverse drug reaction related proteins as a potential tool

for facilitating drug adverse effect prediction. Toxicol. Lett., 164, 104-112.

Bibliography

_________________________________________________________________________


167

John D. Hayes and Roland Wolf, C. (1990). Molecular mechanisms of drug

resistance. Biochem. J., 272, 281-295 (Printed in Great Britain).

John Edwards (1981) http, //www. newdrugdesign. com/Rachel_Theory_04. html

Johnson, A. P. (2001). Curr. Opin. Investig. Drugs, 12, 1691−1701.

Jones, G., Willett, P., Glen, R. C., Leach, A. R. and Taylor, R. (1997).

Development and validation of a genetic algorithm for flexible docking. J.

Mol. Biol., 267, 727-748.

Jouanguy, E. (1999). A human IFNGR1 small deletion hotspot associated with

dominant susceptibility to mycobacterial infection. Nat. Genet., 21, 370-378.

Judson, N. and Mekalanos, J. J. (2000). TnAraOut, a transposon-based approach

to identify and characterize essential bacterial genes. Nat. Biotechnol., 18,

740-745.

Judson, N. and Mekalanos, J. J. (2000). Transposon-based approaches to identify

essential bacterial genes. Trends Microbiol., 8, 521-526.

Kalman, S. (1999). Comparative genomes of Chlamydia pneumoniae and C.

trachomatis. Nat. Genet., 21, 385-389.

Kang, J., Wang, L., Chen, X-L., Triggle, D. J. and Rampe, D. (2001). Interactions

of a series of fluoroquinolone antibacterial drugs with the human cardiac Kþ

channel HERG. Mol. Pharmacol., 59, 122-126.

http://www.newdrugdesign.com/Rachel_Theory_04.html

Bibliography

_________________________________________________________________________


168

Karp, C. L., Grupe, A., Schadt, E., Ewert, S. L. and Keane-Moore, M. (2000).

Identification of complement factor 5 as a susceptibility locus for

experimental allergic asthma. Nat Immunol, 1, 221-226

Karp, P. D. (1999). Integrated pathway-genome databases and their role in drug

discovery. Trends Biotechnol., 17, 275-281.

Kawakami, Y. (1996). Bioorg. Med. Chem., 4, 1429. [PMID, 8894101].

Keenan, R. M. (1993). J. Med. Chem., 36, 1880. [PMID, 8515425].

Kellenberger, E., Rodrigo, J., Muller, P. and Rognan, D. (2004). Comparative

evaluation of eight docking tools for docking and virtual screening accuracy.

Proteins, 57, 225-242.

Kenyon, V., Chorny, I., Carvajal, W. J., Holman, T. R. and Jacobson, M. P. (2006).

Novel human lipoxygenase inhibitors discovered using virtual screening

with homology models. J. Med. Chem., 49, 1356-1363.

Kitchen, D. B., Decornez, H., Furr, J. R. and Bajorath, J. (2004). Docking and

scoring in virtual screening for drug discovery, methods and applications.

Nat. Rev. Drug. Discov., 3(11),935-949. [PubMed,15520816]

Klabunde, T. and Hessler, G. (2002). Chem. Bio. Chem., 3, 928-944.

Klebe, G. (2000). J Mol Med., 78, 269. [PMID, 10954199].

Klebe, G. (2006). Virtual ligand screening, strategies, perspectives and limitations.

Drug Discovery Today, 11(13-14),580-594. [PubMed, 16793526]

Bibliography

_________________________________________________________________________


169

Klein, R. J., Zeis, C., Chew, E. Y., Tsai, J. Y. and Sackler, R. S. (2005).

Complement factor H polymorphism in age-related macular degeneration.

Science, 308, 385-389.

Kobayashi, K., Ehrlich, S. D., Albertini, A., Amati, G., Andersen, K. K., Arnaud, M.,

Asai, K., Ashikaga, S., Aymerich, S. and Bessieres, P. (2003). Essential

Bacillus subtilis genes. Proc. Natl Acad. Sci. USA, 100, 4678-4683.

Koga, A. (1980). J. Med. Chem., 23, 1358 (1980).

Kolonin, M. G. and Finley, R. L. (1998). Targeting cyclin-dependent kinases in

Drosophila with peptide aptamers. Proc. Natl. Acad. Sci. USA, 95, 14266-

14271.

Kotra, L. P., Vakulenko, S. and Mobashery, S. (2000). From genes to sequences

to antibiotics, prospects for future developments from microbial genomics.

2, 651-658.

Kuntz, I. D. (1992). Science, 257, 1078. [PMID, 1509259].

Langer, T., Eder, M., Hoffmann, R. D., Chiba, P. and Ecker, G. F. (2004). Lead

identification for modulators of multidrug resistance based on in silico

screening with a pharmacophoric feature model. Arch Pharm (Weinheim),

337, 317-327.

Lapatto, R. (1989). Nature, 342, 299. [PMID, 2682266].

Bibliography

_________________________________________________________________________


170

Lautenbach, E. and Polk, R. E. (2007). Resistant gram-negative bacilli, A

neglected healthcare crisis? Am. J. Health Syst. Pharm., 1, 64 (23 Suppl

14), S3-21; quiz S22-4.

Lewis, D. F. V. (2000). On the recognition of mammalian microsomal cytochrome

P450 substrates and their characteristics. Biochem. Pharmacol., 60, 293-

306.

Ley, A. B. (1958). Science, 127, 1118.

Li, H., Li, C., Gui, C., Luo, X., Chen, K., Shen, J., Wang, X. and Jiang, H. (2004).

GAsDock, a new approach for rapid flexible docking based on an improved

multi-population genetic algorithm. Bioorg. Med. Chem. Lett., 14, 4671-

4676.

Lill, M. A., Dobler, M. and Vedani, A. (2006). Prediction of small-molecule binding

to cytochrome P450 3A4, flexible docking combined with multidimensional

QSAR. Chem. Med. Chem., 6, 73-81.

Lindquist, S. (1986). Annu. Rev. Biochem., 55, 1151-1191.

Liu, Z., Huang, C., Fan, K., Wei, P., Chen, H. and Liu, S. (2005). Virtual screening

of novel noncovalent inhibitors for SARS-CoV 3C-like proteinase. J. Chem.

Inf. Model., 45, 10-17.

Bibliography

_________________________________________________________________________


171

Lloyd, D. G., Golfis, G., Knox, A. J. S., Fayne, D., Meegan, M. J. and Oprea, T. I.

(2006). Oncology exploration, chartering cancer medicinal chemistry space.

DDT, 11, 149-159.

Loferer, H. (2000). Mining bacterial genomes for antimicrobial targets. Molecular

Medicine Today, 6, 470-474.

Loferer, H., Jacobi, A., Posch, A., Gauss, C., Meier-Ewert, S. and Seizinger, B.

(2000). Integrated bacterial genomics for the discovery of novel

antimicrobials. Drug Discov. Today, 5, 107-114.

Lombardino, J. G. and Lowe III, J. A. (2004). The role of the medicinal chemist in

drug discovery - then and now. Nat. Rev. Drug Discov., 3, 853-862.

Lorenza Bordoli, Florian Kiefer, Konstantin Arnold, Pascal Benkert, James Battey,

and Torsten Schwede (2009). Protein structure homology modeling using

SWISS-MODEL workspace. Nature Protocols, 4, 1-13.

Lorenzen, S., Dunkel, M. and Preissner, R. (2005). In silico screening of drug

databases for TSE inhibitors. Biosystems, 80, 117-122.

Lu, I. L., Huang, C. F., Peng, Y. H., Lin, Y. T., Hsieh, H. P. and Chen, C. T.

(2006). Structure-based drug design of a novel family of PPARgamma

partial agonists, virtual screening, X-ray crystallography, and in vitro/in vivo

biological activities. J. Med. Chem., 49, 2703-2712.

Bibliography

_________________________________________________________________________


172

Luecke, H., Schobert, B., Richter, H. T., Cartailler, J. P. and Lanyi, J. K. (1999).

J. Mol. Biol., 291, 899-911.

Ma, P. and Zemmel, R. (2002). Value of novelty? Nat. Rev. Drug. Discov., 1(8),

571-572.

Mahajan, S. (1999). J. Biol. Chem., 274, 9587. [PMID, 10092645].

Maier, E. (1997). Automated array technologies for gene expression profiling.

Drug Discovery Today, 2, 315-324.

Mao, B., Gozalbes, R., Barbosa, F., Migeon, J., Merrick, S. and Kamm, K. (2006).

QSAR modeling of in vitro inhibition of cytochrome P450 3A4. J. Chem. Inf.

Model, 46, 2125-2134.

Maragakis, L. L., Perencevich, E.N. and Cosgrove, S. E. (2008). Clinical and

economic burden of antimicrobial resistance. Expert Rev. AntiInfect. Ther.

6, 751-63.

McGowan, J. E. Jr. (2006). Resistance in non-fermenting gram-negative bacteria,

multidrug resistance to the maximum. Am. J. Med., 119 (6 Suppl 1), 29-36.

Miesel, L., Greene, J. and Black, T. A. (2003). Genetic strategies for antibacterial

drug discovery. Nature Rev. Genet., 4, 442-456.

Mohan, V., Gibbs, A. C., Cummings, M. D., Jaeger, E. P. and DesJarlais, R. L.

(2005). Docking, successes and challenges. Curr. Pharm. Des., 11,

323-333.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&dopt=Citation&list_uids=12776214

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&dopt=Citation&list_uids=12776214

Bibliography

_________________________________________________________________________


173

Moir, D. T., K. J. Shaw, R. S. Hare, and G. F. Vovis. (1999). Genomics and

antimicrobial drug discovery. Antimicrob. Agents Chemother., 43, 439-446.

Mootha, V. K., Lindgren, C. M., Eriksson, K. F., Subramanian, A. and Sihag, S.

(2003). PGC-1alpha-responsive genes involved in oxidative

phosphorylation are coordinately downregulated in human diabetes. Nat.

Genet., 34, 267-273.

Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K.

and Olson, A. J. (1998). Automated docking using a Lamarckian Genetic

Algorithm and an empirical binding Free Energy Function. J. Comput.

Chem., 19, 1639-1662.

Muegge, I. and Enyedy, I. J. (2004). Virtual screening for kinase targets. Curr.

Med. Chem., 11, 693-707.

Mushegian, A. R. and Koonin, E. V. (1996). A minimal gene set for cellular life

derived by comparison of complete bacterial genomes. Proc. Natl. Acad.

Sci. USA, 93, 10268-10273.

Myers, P. L. (1997). Will combinatorial chemistry deliver real medicines? Curr.

Opin. Biotechnol., 8, 701-707.

Nilsen, T. W. (2001). Method for identifying essential or functional genes. US

Patent, 6, 248, 525.

Bibliography

_________________________________________________________________________


174

Nisbet, L. J. and Moore, M. (1997). Will natural products remain an important

source of drug research for the future? Curr. Opin. Biotechnol., 8, 708-712.

Nuwaysir, E. F. (1999). Microarrays and toxicology, The advent of toxicogenomics.

Mol. Carcinog., 24, 153-159.

Oren M. Becker, Yael Marantz, Sharon Shacham, Boaz Inbal, Alexander Heifetz,

Ori Kalid, Shay Bar-Haim, Dora Warshaviak, Merav Fichman, and Silvia

Noiman (2004). G protein-coupled receptors, In silico drug discovery in 3D,

101, 11304-11309.

Ozdemir, V., Shear, N. H. and Kalow, W. (2001). What will be the role of

pharmacogenetics in evaluating drug safety and minimizing adverse

effects? Drug Safety, 24, 75-85.

Paige, L. A. (1999). Estrogen receptor (ER). modulators each induce distinct

conformational changes in ERa and ERb. Proc. Natl. Acad. Sci. USA, 96,

3999-4004.

Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A.,

Trong, I. L., Teller, D. C., Okada, T. and Stenkamp, R. E. (2000). Science,

289, 739-745.

Palmer, L. M., Pratt, J. M. and Rosenberg, M. (2000). Method for determining

gene essentiality in a pathogen. US Patent, 6, 139, 817.

Bibliography

_________________________________________________________________________


175

Paolini, G. V., Shapland, R. H., Van Hoorn, W. P., Mason, J. S. and Hopkins, A. L.

(2006). Global mapping of pharmacological space. Nat. Biotechnol., 24,

805-815.

Paul, N., Kellenberger, E., Bret, G., Muller, P. and Rognan, D. (2004). Recovering

the true targets of specific ligands by virtual screening of the protein data

bank. Proteins, 54, 671-680.

Peacock, M. L., Warren, J. T. Jr, Roses, A. D. and Fink, J. K. (1993). Novel

polymorphism in the A4 region of the amyloid precursor protein gene in a

patient without Alzheimer’s disease. Neurology, 43, 1254-1256.

Pebay-Peyroula, E., Rummel, G., Rosenbusch, J. P. and Landau, E. M. (1997).

Science, 277, 1676-1681.

Pellecchia, M. (2002). Nat. Rev. Drug Discov., 1, 211. [PMID, 12120505].

Pleban, K., Kaiser, D., Kopp, S., Peer, M., Chiba, P. and Ecker, G. F. (2005).

Targeting drug-efflux pumps - a pharmacoinformatic approach. Acta.

Biochim. Pol., 52, 737-740.

Poroikov, V. V., Filimonov, D. A., Borodina, Y. V., Lagunin, A. A. and Kos, A.

(2000). Robustness of biological activity spectra predicting by computer

program PASS for non-congeneric sets of chemical compounds. J. Chem.

Inf. Comput Sci., 40, 1349–1355.

Bibliography

_________________________________________________________________________


176

Prentis, R. A., Lis, Y. and Walker, S. R. (1988). Pharmaceutical innovation by the

seven UK-owned pharmaceutical companies (1964-1985). Br J Clin

Pharmacol., 25, 387-96.

Projan, S. (2002). Curr. Opin. Pharmacol., 2, 513−522.

Rarey, M., Kramer, B., Lengauer, T. and Klebe, G. (1996). A fast flexible docking

method using an incremental construction algorithm. J. Mol. Biol., 261, 470-

489.

Rattner, A., Sun, H. and Nathans, J. (1999). Annu. Rev. Genet., 33, 89-131.

Reich, K. A., Chovan, L. and Hessler, P. (1999). Genome scanning in

Haemophilus influenzae for identification of essential genes. J. Bacteriol.,

181, 4961-4968.

Rockey, W. M. and Elcock, A. H. (2005). Rapid computational identification of the

targets of protein kinase inhibitors. J. Med. Chem., 48, 4138-4152.

Rodrigues, A. D. and Lin, J. H. (2001). Curr. Opin. Chem. Biol., 5, 396-401.

Rodrigues, A. D. and Rushmore, T. H. (2002). Cytochromep450

pharmacogenetics in drug development, in vitro studies and clinical

consequences. Curr. Drug. Metab., 3, 289-309.

Rollinger, J. M., Bodensieck, A., Seger, C., Ellmerer, E. P., Bauer, R. and Langer,

T. (2005). Discovering COX-inhibiting constituents of Morus root bark,

activity-guided versus computer-aided methods. Planta. Med., 71, 399-405.

Bibliography

_________________________________________________________________________


177

Rollinger, J. M., Hornick, A., Langer, T., Stuppner, H. and Prast, H. (2004).

Acetylcholinesterase inhibitory activity of scopolin and scopoletin

discovered by virtual screening of natural products. J. Med. Chem., 47,

6248-6254.

Rosamond, L. and Allsop, A. (2000). Harnessing the power of the genome in the

search for new antibiotics. Science, 287, 1973-1976.

Roses, A. D. (2000). Pharmacogenetics and the practice of medicine. Nature, 405,

857-65.

Roth, B. L., Lopez, E., Beischel, S., Westkaemper, R. B. and Evans, J. M. (2004).

Screening the receptorome to discover the molecular targets for plant-

derived psychoactive compounds, a novel approach for CNS drug

discovery. Pharmacol. Ther., 102, 99-110.

Rowland, P., Blaney, F. E., Smyth, M. G., Jones, J. J., Leydon, V. R., Oxbrow, A.

K. (2006). Crystal structure of human cytochrome P450 2D6. J. Biol. Chem.,

281, 7614-7622.

Sakharkar, K. R., Sakharkar, M. K. and Chow, V. T. K. (2004). A novel genomics

approach for the identification of drug targets in pathogens, with special

reference to Pseudomonas aeruginosa. In Silico Biol., 4, 28.

Sali, A. and Blundell, T. L. (1993).Comparative protein modelling by satisfaction of

spatial restraints. J. Mol. Biol., 234, 779-815.

http://www.bioinfo.de/isb/2004/04/0028/



Bibliography

_________________________________________________________________________


178

Samson, L. and Cairns, J. (1977). Nature (London). 267, 281-283.

Sandra Kraljevic, Peter J. Stambrook and Kresimir Pavelic (2004). Accelerating

drug discovery. EMBO Reports, 5, 837-842.

Sautel, M. and Milligan, G. (2000). Curr. Med. Chem., 7, 889-896.

Schadt, E. E. and Lum, P. Y. (2006). Reverse engineering gene networks to

identify key drivers of complex disease phenotypes. J. Lipid. Res., 47(12),

2601-2613.

Schadt, E. E., Monks, S. A., Drake, T. A., Lusis, A. J. and Che, N. (2003).

Genetics of gene expression surveyed in maize, mouse and man. Nature,

422, 297-302.

Schapira, M., Raaka, B. M., Samuels, H. H. and Abagyan, R. (2000). Rational

discovery of novel nuclear hormone receptor antagonists. Proc. Natl. Acad.

Sci. USA, 97, 1008-1013.

Schmid, M. B. (1989). Genetic analysis of temperature-sensitive lethal mutants of

Salmonella typhimurium. Genetics, 123, 625-633.

Schmid, M. B. (1998). Novel approaches to the discovery of antimicrobial agents.

Curr. Opin. Chem. Biol., 2, 529-534.

Schoneberg, T., Schulz, A. and Gudermann, T. (2002). Rev. Physiol. Biochem.

Pharmacol., 144, 143-227.

Bibliography

_________________________________________________________________________


179

Service, R. F. (1998). Microchip arrays put DNA on the spot. Science, 282, 396-

399.

Shacham, S., Marantz, Y., Bar-Haim, S., Kalid, O., Warshaviak, D., Avisar, N.,

Inbal, B., Heifetz, A., Fichman, M. and Topf, M. (2004). Proteins.

Shacham, S., Topf, M., Avisar, N., Glazer, F., Marantz, Y., Bar-Haim, S., Noiman,

S., Naor, Z. and Becker, O. M. (2001). Med. Res. Rev., 21, 472-483.

Shao, D., Berrodin, T. J., Manas, E., Hauze, D., Powers, R. and Bapat, A. (2004).

Identification of novel estrogen receptor alpha antagonists. J. Steroid.

Biochem. Mol. Biol., 88, 351-360.

Shen, J., Xu, X., Cheng, F., Liu, H., Luo, X., Shen, J., Chen, K., Zhao, W., Shen,

X. and Jiang, H. (2003). Virtual screening on natural products for

discovering active compounds and target information. Curr. Med. Chem.,

10, 2327-2342.

Shi, Y. (2006). Orphan nuclear receptors, excellent targets of drug discovery.

Comb. Chem. High. Throughput Screen, 9, 683-689.

Shoichet, B. K. (2004). Virtual screening of chemical libraries. Nature 432(7019),

862-865. [PubMed,15602552]

Sibanda, B. L. (1983). Nature, 304, 273. [PMID, 6346109].

Sieburg, H. B. (1990). Physiological studies in silico. Studies in the Sciences of

Complexity, 12, 321-342.

Bibliography

_________________________________________________________________________


180

Sladek, R., Rocheleau, G., Rung, J., Dina, C. and Shen, L. (2007). A genome-

wide association study identifies novel risk loci for type 2 diabetes. Nature,

445, 881-885.

Smider, V., Rathmell, W. K., Lieber, M. and Chu, G. (1994). Restoration of X-ray

resistance and V(D)J recombination in mutant cells by Ku cDNA. Science,

266, 288-291.

Smith, D. R. (1996). Microbial pathogen genomes - new strategies for identifying

therapeutics and vaccine targets. Trends Biotechnology, 8, 290-293.

Smith, V., Botstein, D. and Brown, P. O. (1995). Genetic footprinting, a genomic

strategy for determining a gene’s function given its sequence. Proc. Natl.

Acad. Sci. USA, 92, 6479-6483.

Smith, V., Chou, K. N., Lashkari, D., Botstein, D. and Brown, P. O. (1996).

Functional analysis of the genes of yeast chromosome V by genetic foot-

printing. Science, 274, 2069-2074.

Snodin, D. J. (2002). An EU perspective on the use of in vitro methods in

regulatory pharmaceutical toxicology. Toxicol. Lett., 127, 161-168.

Stark, G. R. (1986). Cancer Surveys, 5, 1-23.

Steindl, T. and Langer, T. (2004). Influenza virus neuraminidase inhibitors,

generation and comparison of structure-based and common feature

Bibliography

_________________________________________________________________________


181

pharmacophore hypotheses and their application in virtual screening.

J. Chem. Inf. Comput Sci., 44, 1849-1856.

Steindl, T. M., Crump, C. E., Hayden, F. G. and Langer, T. (2005a).

Pharmacophore modeling, docking, and principal component analysis

based clustering, combined computer-assisted approaches to identify new

inhibitors of the human rhinovirus coat protein. J. Med. Chem., 48, 6250-

6260.

Steindl, T., Laggner, C. and Langer, T. (2005b). Human rhinovirus 3C protease,

generation of pharmacophore models for peptidic and nonpeptidic inhibitors

and their application in virtual screening. J. Chem. Inf. Model, 45, 716-724.

Storz, G., Tartaglia, L. A. and Ames, B. N. (1990). Science, 248, 189-194.

Stover, C. K., Pham, X. Q., Erwin, A. L., Mizoguchi, S. D., Warrener, P., Hickey,

M. J., Brinkman, F. S., Hufnagle, W. O., Kowalik, D. J. and Lagrou, M.,

(2000). Nature, 406, 959−964.

Strachan, R. T., Ferrara, G. and Roth, B. L. (2006). Screening the receptorome, an

efficient approach for drug discovery and target validation. Drug Discov.

Today, 11, 708-716.

Sudbeck, E. A. (1999). Clin. Cancer Res., 5, 1569. [PMID, 10389946].

Swaan, P. W. and Ekins, S. (2005). Reengineering the pharmaceutical industry by

crash-testing molecules. Drug Disc. Today, 10, 1191-1200.

Bibliography

_________________________________________________________________________


182

Taccioli, G. E. (1994). Ku80, product of the XRCC5 gene and its role in DNA

repair and V(D)J recombination. Science, 265, 1442-1445.

Tatusov, R. L. (1997). A genomic perspective on protein families. Science, 278,

631-637.

Terlau, H. and Stuhmer, W. (1998). Structure and function of voltage-gated ion

channels. Naturwissenschaften, 85, 437-444.

Tesmer, J. J. G. (2006). Hitting the hot spots of cell signaling cascades. Science,

312, 377-378.

Testa, B. and Kraämer, S. D. (2006). The biochemistry of drug metabolism - an

introduction. Part 1, principles and overview. Chem. Biodivers., 3, 1053-

1101.

Timberlake, W. and Gavrias, V. (1999). Identification of essential survival genes.

US Patent, 5, 976, 828.

Tsuchida, K., Chaki, H., Takakura, T., Kotsubo, H., Tanaka, T. and Aikawa, Y.

(2006). Discovery of nonpeptidic small-molecule AP-1 inhibitors, lead

hopping based on a three-dimensional Pharmacophore model. J. Med.

Chem., 49, 80-91.

Van Dongen, M. J., Uppenberg, J., Svensson, S., Lundback, T., Akerud, T.,

Wikstrom, M. and Schultz, J. (2002). J. Am. Chem. Soc., 124, 11874-

11880.

Bibliography

_________________________________________________________________________


183

Van’t Veer, L. J., Dai, H., Van de Vijver, M. J. and He, Y. D. (2002). Gene

expression profiling predicts clinical outcome of breast cancer. Nature, 415,

530-536

Vankayalapati, H. (2003). Mol. Cancer Ther., 2, 283. [PMID, 12657723]

Varady, J., Wu, X., Fang, X., Min, J., Hu, Z., Levant, B. and Wang, S. (2003).

J. Med. Chem., 46, 4377-4392.

Varghese, J. N. (1999). Drug Dev. Res., 46, 176.

Veber, D. F. (1992). Peptides, Chemistry, and Biology. Proceedings of the 12th

American Peptide Symposium, eds. Smith, J. A. and Rivier, J. E. (ESCOM,

Leiden, The Netherlands), pp. 3-14.

Venter, J. C. (2001). Science, 291, 1304. [PMID, 11181995].

Vieth, M., Higgs, R. E., Robertson, D. H., Shapiro, M., Gragg, E. A. and

Hemmerle, H. (2004). Kinomics-structural biology and chemogenomics of

kinase inhibitors and targets. Biochim. Biophys. Acta., 1697, 243-257.

Walker, G. C. (1985). Annu. Rev. Biochem., 54, 425-457.

Walters, P. W. (1998). Drug Discovery Today, 3, 160.

Wang, R., Fang, X., Lu, Y. and Wang, S. (2004). The PDBBind

database,collection of binding affinities for protein–ligand complexes with

known three-dimensional structures. J. Med. Chem., 47, 2977–2980.

Bibliography

_________________________________________________________________________


184

Watson K. C., Jourbert, S. M., and Bennett, M. A. E. (1959). Nature (Lond. ), 183,

468.

Whittaker, P. A. (2003). What is the relevance of bioinformatics to pharmacology?

Trends Pharmacol. Sci., 24, 434-439.

Whittle, P. J. and Blundell, T. L. (1994). Protein structure based drug design.

Annu. Rev. Biophys. Biomol. Struct., 23, 349-375.

Wilson, M. (1999). Exploring drug-induced alterations in gene expression in

Mycobacterium tuberculosis by microarray hybridization. Proc. Natl. Acad.

Sci. USA, 96, 12833-12838.

Wilson, S. and Bergsma, D. (2000). Drug Des. Discovery, 17, 105-114.

Wise, A., Jupe, S. C. and Rees, S. (2004). The identification of ligands at orphan

G-protein coupled receptors. Annu. Rev. Pharmacol. Toxicol., 44, 43-66.

Wishart, D. S., Knox, C, Guo, A. C., Shrivastava, S., Hassanali, M. and Stothard,

P. (2006). DrugBank, a comprehensive resource for in silico drug discovery

and exploration. Nucleic Acids Res., 34, D668-D672.

Wlodawer, A. and Vondrasek, J. (1998). Annu. Rev. Biophys. Biomol. Struct., 27,

249. [PMID, 9646869].

Wolber, G. and Langer, T. (2005). LigandScout, 3-D pharmacophores derived

from protein-bound ligands and their use as virtual screening filters.

J. Chem. Inf. Model, 45, 160-169.

Bibliography

_________________________________________________________________________


185

Wong, B. R., Parlati, F., Qu, K., Demo, S., Pray, T. and Huang, J. (2003). Drug

discovery in the ubiquitin regulatory pathway. Drug Discov. Today, 8,

746-754.

Wong, S. M. and Mekalanos, J. J. (2000). Genetic footprinting with marinerbased

transposition in Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. USA, 97,

10191-10196.

Wrighton, N. C. (1996). Small peptides as potent mimetics of the protein hormone

erythropoietin. Science, 273, 458-464.

Yu, J., Paine, M. J., Marechal, J. D., Kemp, C. A., Ward, C. J. and Brown, S.

(2006). In silico prediction of drug binding to CYP2D6, identification of a

new metabolite of metoclopramide. Drug Metab. Dispos., 34, 1386-1392.

Zhang, E. Y., Knipp, G. T., Ekins, S. and Swaan, P. W. (2002a). Structural biology

and function of solute transporters, implications for identifying and designing

substrates. Drug Metab. Rev., 34, 709-750.

Zhang, E. Y., Phelps, M. A., Cheng, C., Ekins, S. and Swaan, P. W. (2002b).

Modeling of active transport systems. Adv. Drug. Del. Rev., 54, 329-354.

Zhao, L. and Brinton, R. D. (2005). Structure-based virtual screening for plant-

based ERbeta-selective ligands as potential preventative therapy against

age-related neurodegenerative diseases. J. Med. Chem., 48, 3463-3466.

Bibliography

_________________________________________________________________________


186

Website

http,//www. archive. org/details/arsdigita_04_java

http,//www.chestjournal.org/content/79/4_Supplement/38S The Discovery of

Penicillin Br Med J., 1955 March 19; 1(4915), 711.

http,//www. java2s. com/

http,//www. javaworld. com/javaworld/jw-06-1999/jw-06-javamail. html

http,//www. sun. com

____

`

http://www.archive.org/details/arsdigita_04_java

http://www.chestjournal.org/content/79/4_Supplement/38S

http://www.javaworld.com/javaworld/jw-06-1999/jw-06-javamail.html

http://www.sun.com/

Education

Bibliography for the Drug Target Identification from Microbial Genomes